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Abstract
Purpose: The purpose of the study was to validate [18F]DPA-714, a translocator protein (TSPO)
18 kDa radioligand, as a probe to non-invasively quantify the inﬂammatory state in inﬂammatory
bowel disease (IBD) animal models.
Procedures: Quantitative positron emission tomography (PET) imaging of intestinal inﬂamma-
tion was conducted with 2-deoxy-2-[18F]ﬂuoro-D-glucose ([18F]FDG) a glucose metabolism
surrogate marker and [18F]DPA-714 a ligand of the 18 kDa TSPO, on two IBD models. The ﬁrst
model was induced using dextran sodium sulfate (DSS), creating global inﬂammation in the
colon. The second model was induced by rectally administering trinitrobenzenesulfonic acid
(TNBS), creating local and acute inﬂammation.
Results: The level of inﬂammation was analyzed using PET imaging on days 7 and 8. The analysis
obtained with [18F]DPA-714, yielded a signiﬁcant difference between the DSS treated (0.50±
0.17%ID/cc) and non-treated rats (0.35±0.15%ID/cc). [18F]FDG on the other hand did not yield a
signiﬁcant difference. We did observe a mean glucose consumption in the colon increase from 0.40
±0.11%ID/cc to 0.54±0.17%ID/cc. In the TNBSmodel, the uptake level of [18F]DPA-714 increased
signiﬁcantly from0.46±0.23%ID/cc for the non-treated group, to 1.30±0.62%ID/cc for those treated.
PET signal was correlated with increased TSPO expression at cellular level.
Conclusions: Results indicate that [18F]DPA-714 is suitable for studying inﬂammation in IBD
models. [18F]DPA-714 could be a good molecular probe to non-invasively evaluate the level and
localization of inﬂammation. Moreover, in vivo imaging using this TSPO ligand is potentially a
powerful tool to stage and certainly to follow the evolution and therapeutic efﬁciency at
molecular level within this disease family.
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Introduction
Inﬂammatory bowel disease (IBD) is a disease family thathas not been getting the attention that it warrants. The
incidence has been slowly rising throughout much of the
industrialized world, and is not limited to adults, but also
affects children [1].
IBD is comprised of multiple diseases, including Crohn’s
disease (CD) and ulcerative colitis (UC), which all have
aspects of inﬂammatory responses, ranging from acute to
chronic stages, and in many cases include both. The whole
gastrointestinal tract can be affected from CD while UC is
limited to the cecum, colon, and rectum [2]. PreciseCorrespondence to: Raphael Boisgard; e-mail: raphael.boisgard@cea.fr
localization of the inﬂamed sites is one criteria permitting
differential diagnosis between different types of diseases.
The fact that this disease family can have such large
variations, and yet present itself with similar if not identical
symptoms, makes it very difﬁcult to diagnose and to
differentiate. The origins of the diseases are unknown, but
there seems to be a tendency for the disease to be more
prevalent in the Western world, and in particular, within
urban areas; this is not to say that the levels or the incidence
outside of the urban Western world are lower, but rather that
the methods of detection and deﬁnition of what constitutes
IBD are similar in these areas [3]. There may be multiple
factors which contribute to the development of the diseases
ranging from genetic pre-dispositions to lifestyle and stress
exposure [4].
Inﬂammation is only the beginning of medical concerns
associated with IBD. If IBD is left untreated, it can lead to
cancer of the intestine. Even if this does not happen, there is
still a detrimental impact on daily lifestyle. It is not
completely clear how to avoid suffering from IBD, but early
detection would allow early treatment and thus represent a
way by which suffering could be minimized. Moreover, the
disease progression and evaluation of the therapeutic
efﬁciency also lack pertinent criteria.
Currently, the clinical evaluation consists of various
exams and exam types ranging from physical symptoms,
such as bloody diarrhea (a cardinal symptom), to serology,
endoscopic exploration, radiological analysis, and nuclear
medical investigations [5]. Preclinical investigations often-
times use rodents which have had IBD symptoms induced
by various means. The general assessment of IBD in vivo is
commonly carried out by observing bloody diarrhea and by
scoring body weight changes. Post mortem analyses include
measurements of the colon length, cytokine and chemokine
concentrations along with histological scoring [6]. These last
years, only few articles illustrate the interest of in vivo
imaging using a non-speciﬁc radiotracer, which is based on
the increase of glucose metabolism, for the evaluation of
IBD in both human and preclinical models [7, 8].
In vivo molecular imaging represents an attractive means
to characterize these types of pathologies, especially as it is
non-invasive. Of these methods, positron emission tomog-
raphy (PET) is a powerful technique allowing the clinician
to access molecular information in vivo. PET imaging has
been present in clinical applications since the 1970s and is
now routinely used for diagnosis, prognosis, and
theranostics. Due to the fact that it is a quantitative, speciﬁc,
and sensitive imaging modality, this non-invasive in vivo
technique is well adapted for early detection of various
diseases. PET is, however, based on the use of dedicated
radiotracers, the most well-known being 2-deoxy-2-
[18F]ﬂuoro-D-glucose ([18F]FDG), a surrogate marker for
glucose metabolism. Recently, Lapp, but also Shyn and
Ostuni and collaborators have shown that PET could indeed
be used for the detection of an IBD related disease with the
use of [18F]FDG [9–11].
[18F]DPA-714 is a recently developed radioligand of the
translocator protein 18 kDa (TSPO) with improved signal to
noise ratios as compared to previously used radiotracers and
especially [11C]PK11195 [12, 13]. TSPO, formerly known
as peripheral benzodiazepine receptor (PBR), located on the
outer membrane of the mitochondria, is overexpressed in
activated macrophages and microglia. This molecular event
has been used widely to investigate inﬂammation inside the
central nervous system. TSPO increase in microglia is now
presented as a hallmark of brain inﬂammation and our
laboratories have been instrumental in the characterization
and validation of this radiotracer in various preclinical
models of neuroinﬂammation [14, 15]. However, when
looking at peripheral activation of macrophages and links
to the inﬂammatory processes, little data are currently
available. TSPO expression was recently described in tissue
samples of human colon suffering from IBD (CD and UC)
[11]. Additionally, expression has also been characterized in
a rat model of IBD using autoradiography and immunohis-
tochemistry [11].
The use of the TSPO ligand [18F]DPA-714 has opened
doors to exploration into inﬂammation within the periphery,
and thus also into the domain of inﬂammatory bowel diseases.
It allows the quantiﬁcation of the inﬂammation found in a
given area within the bowel. To conﬁrm this capability, we
implemented two animal models of IBD, one using dextran
sodium sulfate (DSS) inducing high diffuse inﬂammation in
the colon, and the other using trinitrobenzenesulfonic acid
solution (TNBS) inducing inﬂammation mainly restricted in
the area of instillation [16, 17], and demonstrated the potential
of [18F]DPA-714 to image IBD with PET.
Materials and Methods
Animal Models
The animals chosen were male Wistar rats (Centre d’Elevage René
Janvier, France) with a weight of 250 g±20 g. The subjects were
kept in an adapted environment in which the temperature and
humidity are regulated. The lights are on a 12-h cycle on and then
off. The experiments were carried out in accordance with French
guidelines.
Two different animal models of acute bowel inﬂammation were
developed and implemented in the study. The ﬁrst being a DSS
(Sigma-Aldrich, France; MW40,000) induced model, which leads
to haematochezia, and also to weight loss along with a shortening
of the intestine among other consequences associated with a colitis
rat model [16]. DSS induces in vivo intestinal inﬂammation and is
simple, affordable, and also has a high degree of uniformity and
reproducibility of most lesions in the distal colon. In this model, we
added DSS at 5 % (v:v) into the drinking water of the animals from
which they had ad libitum access throughout the duration of the
experiments. [18F]FDG images were acquired after 7 days of
treatment whereas [18F]DPA-714 images were acquired after 8 days
of treatment. The treatment has been used successfully with rats in
previous tests [18]. Non-treated rats were given plain water in their
bottles and all the animals were weighed daily, and their feces state
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was also observed on a daily schedule. The DSS solution was
exchanged on days 3 and 5 in the treated group and the non-treated
group also had their water exchanged for a new bottle containing
plain water at the same time points.
The second model was chemically induced by instilling
trinitrobenzenesulfonic acid (TNBS) (Sigma-Aldrich) as described
by the group of Seibel et al. [19]. Some slight alterations were
made in order to adapt this model to the PET modality. Here,
inﬂammation was induced into male Wistar rats by administering
100 μl of 50 % ethanol-water solution (to help bypass the mucosal
layer of the intestine) containing TNBS (100 g/l, corresponding to
40 mg/kg body weight) 4 cm into the rectum from the anus [17].
During this administration, the rats were under anesthesia using
2.5 % isoﬂurane in 100 % O2. This anesthesia was maintained for
an extra 10 min post instillation in order to reduce displacement and
possible leakage of the chemical. Non-treated animals were injected
with 100 μl of ethanol and water (1/1, v:v).
The animals were then placed into individual cages and their
weights were measured on a daily basis and their feces state was
recorded. Inﬂammation was evaluated with PET imaging on day 7
using [18F]FDG and on day 8 using [18F]DPA-714 after TNBS
administration.
PET Radiotracer
[18F]FDG was purchased from the commercially available source
Cyclopharma S.A. (Clermont-Limagne, France). [18F]DPA-714
was produced on site according to slight modiﬁcations of
procedures already reported [20] and using a commercially
available GE TRACERLab FX-FN synthesizer [21]. Ready-to-
inject, 999 % radiochemical pure [18F]DPA-714 (formulated in
physiological saline containing less than 10 % of ethanol) was
obtained with 15–20 % non-decay-corrected yields and speciﬁc
radioactivitiy level at the end of the radiosynthesis ranging from 37
to 111 GBq/μmol.
Image Acquisition
The PET and PET/CT images were acquired using two separate
machines. The ﬁrst one is a Siemens INVEON PET and the second
a Siemens INVEON PET/CT, both being dedicated small animal
scanners. Each animal had its images acquired in the same machine
each day. The animals were kept normothermic with the help of a
heating carpet. Rats were anesthetized using 3 % isoﬂurane in pure
oxygen and kept sedated throughout the acquisition. For [18F]DPA-
714, images were acquired dynamically during a time span of
60 min, beginning at the same time as the injection. Each animal
was injected with 37±2 MBq (1.0 mCi±0.054 mCi). The [18F]FDG
acquisitions (30 min) were sorted into three frames of 10 min each
and the [18F]DPA-714 images were sorted into 16 frames. Frames
1–5 each lasted 1 min, frames 6–10 lasted 2 min, frames 11–13
each lasted 5 min, and the remaining frames (14–16) lasted for
10 min each. The energy discrimination was set at 350 and
650 KeV. The list-mode acquisition was as described previously
and the data ﬁles were histogrammed into three-dimensional
sinograms with a maximum difference of 47 and a span of 3 [20].
The attenuation correction of the Siemens INVEON PET was
measured with the help of a Cobalt-57 point source. The Siemens
INVEON PET/CT carried out the attenuation correction
measurement with the use of its CT imaging capabilities and
settings, which are implemented directly by the manufacturer. In
order to obtain the best resolution possible within the intestines, we
implemented a Fourier rebinning and an OSEM 2D reconstruction
method.
Image Analysis
The reconstructions of the PET images were carried out using
ASIPro VM (CTI Concorde Microsystem Analysis Tools and
System Setup/Diagnostic Tool). The image analysis and quantiﬁ-
cation of the radioactivity uptake in the regions and volumes of
interest (ROI’s and VOI’s) were carried out with the use of
BrainVisa/Anatomist Version 4.3.0 [22].
Delineation of the ROI’s and VOI’s was selected by means of
manual segmentation and always carried out by the same user. The
selected region of the intestine was 5×3×2 voxels, or a 3.6-mm3
volume placed on the intestinal wall.
Gamma Counting
The ascending colon was excised once the subject had been
euthanized via an i.v. injection of pentobarbital and divided
into three sections. Each sample was weighed before being
placed into individual tubes, which were then inserted into a
Perkin Elmer Cobra II Auto-Gamma Gamma-ray counter. The
results were decay-corrected and standardized for the percent
injected dose, sample weight, and the body weight of each




Post mortem tissue samples were excised, once the [18F]DPA-714
images had been acquired, and ﬁxed with 4 % paraformaldehyde
(PFA, Sigma-Aldrich) in Phosphate-buffered saline (PBS, pH 7.4
Sigma-Aldrich, France) for 2 h followed by cryopreservation by
incubation in PBS, pH 7.4 containing 20 % sucrose for 24 h. The
intestines were then cut into thirds (ascending, transverse, and
descending sections), immersed in embedding tissue medium
(Shandon M-1 Embedding Matrix, Thermo, USA), and frozen
rapidly in liquid nitrogen. Immunohistochemistry (IHC) was then
carried out on slices of 5 μm thickness taken from the specimen.
Anti-TSPO marker (NP-155, a kind gift of Dr. Makoto Higuchi,
The National Institute of Radiological Sciences, Chiba, Japan) was
used on individual slices.
Non-speciﬁc binding were blocked with 5 % BSA and 0.5 %
Tween 20 in PBS (5 min, room temperature (RT)) and incubated
(1 h, RT) with primary antibodies as follows: Rabbit anti-TSPO
antibody (NP155, 1:500) diluted in 5 % BSA and 0.5 % Tween 20
in PBS, and, after PBS washes (three times), sections were
incubated (30 min, RT) with Alexa Fluor-488 goat anti-rabbit
(A11034, 1:1000; Invitrogen, France), diluted in 5 % BSA and
0.5 % Tween 20 in PBS.
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Hematoxylin and Eosin Staining
The frozen slides containing slices of the intestines were placed into
fresh PBS for rehydration 5 min before being placed into deionized
water for 1 min. The slides were then introduced for 5 min into a
Hematoxylin solution ready to use (Sigma-Aldrich, France). Once
this was carried out, the slides were placed into tap water for 5 min
before being placed into a series of 5-min-baths of deionized water,
followed by Eosin-Y solution (LABOnord, Templemars, France),
90 % ethanol in water, 100 % ethanol, and ﬁnally toluene for
15 min. Once this was done, the slides were individually mounted
with the Eukitt quick-hardening mounting medium (Sigma-Aldrich,
France), by placing a few drops onto the slide and then laying a
cover slip over them.
Results
As illustrated by the group of Lacapere, there is an
overexpression of TSPO in the rat colon of the DSS-induced
IBD animal model after 7 days of treatment [11]. To
evaluate the possibility to both visualize and quantify the
expression of TSPO in IBD, we reproduced the inﬂamma-
tory model in our laboratories. In the DSS rat model, large
alterations to the structure of the colon can be observed
when compared with samples of non-treated animals, as
illustrated in Fig 1. Microscopic observations on the
different sections of the colon (ascending, transverse, and
descending) of treated animals revealed erosion along the
entire colon. This alteration was also associated with rectal
bleeding and a loss of weight in treated animals (data not
shown). The non-treated animals showed no such signs and
have intact crypts as illustrated on Fig. 1a. TSPO expression
was investigated on adjacent tissue samples. Representative
images (Fig. 1e, f) clearly show the increased presence of
TSPO in the colon of treated animals with high inﬁltration in
the eroded lamina propria and high density at the base of the
intestinal wall (lamina muscularis/mucosae). In comparison
to non-treated animals, TSPO positive cells were mainly
found at a lower density within the lamina propria (Fig. 1d).
In the TNBS model, due to the direct local adminis-
tration of the inﬂammatory agent, the phenotype was
different with the inﬂammation localized mainly in the
upper part of the ascending colon (around 4 cm from the
anus), as opposed to the global inﬂammation found in
the ﬁrst (DSS) model. In this second model, the H&E
staining presented in Fig. 1a, c indicates a morphological
difference between a treated animal and a healthy
animal, as indicated by an alteration of the microvilli
architecture of the colon in the area of instillation. TSPO
staining revealed an accumulation of TSPO positive cells
at the base (lamina mucosae) and at the extremity of the
microvilli (Fig. 1f).
In order to investigate the utility of [18F]DPA-714 to
provide information concerning the inﬂammatory processes
in vivo, we performed PET imaging on non-treated and
treated rats and compared the uptake of this TSPO
radioligand with [18F]FDG, a radiotracer used previously to
visualize IBD in humans. A PET imaging session was
carried out on day 7 post treatment induction, using
[18F]FDG, and on day 8 with [18F]DPA-714 on the same
animals.
Figure 2 illustrates representative images of non-
treated (2a, c) and DSS treated animals (2b, d) using
[18F]FDG (2a, b) and [18F]DPA-714 (2c, d) at 7 and
8 days, respectively, along with the corresponding graphs
(Figure 2 e, f, respectively). For both tracers, an
increased uptake in the colon of treated animals in
comparison to non-treated animals was observed. The
regions of interest were manually drawn with identical
sizes for all images on the colon wall in the area with
the highest signal. Quantiﬁcation of the radioactivity
uptake after 60 min of acquisition revealed that for
[18F]FDG, the mean glucose consumption in the colon
increased from 0.40±0.11 %ID/cc to 0.54±0.17 %ID/cc
(Fig. 2). This increase identiﬁed the inﬂammatory
processes but was not sufﬁciently high to provide a
signiﬁcant difference between the two groups of rats (P=
0.053). Similarly, quantiﬁcation of [18F]DPA-714 in the
colon of control and treated animals revealed a signiﬁ-
cant increase in uptake level from 0.35±0.15 %ID/cc to
0.50±0.17 %ID/cc (P=0.040, Fig. 2). This increased
signiﬁcance correlates to the overexpression of TSPO in
colon tissue samples as illustrated on the Fig. 1e.
In Fig. 3, one can observe that the PET images and
the subsequent analysis, were veriﬁed/validated with the
gamma counting. Here, we also observed a signiﬁcant
difference between the treated and control groups where
pG0.0001.
In the TNBS model, in contrast to the DSS model, the
inﬂammation is localized mainly in the area of administra-
tion of the immunogenic stimulating agent. PET image
analysis clearly illustrated that [18F]DPA-714 was able to
highlight a difference in inﬂammatory status between the
non-treated and the treated animals. Figure 4 illustrates the
increased uptake for both tracers (images a–d and graphs e
and f), [18F]FDG and [18F]DPA-714. Treated animals
(Fig. 4b, d) show a more localized area of inﬂammation
when compared to the distribution of the tracers in the DSS
model (Fig. 2b, d). For both tracers, the area of increasing
signal is larger than the theoretical area of instillation due to
either a diffusion of the TNBS during experimental
procedure or to a propagation of inﬂammation to a large
portion of this organ.
For both [18F]FDG and [18F]DPA-714, the inﬂammation
induced a signiﬁcant increase of tracer accumulation from
0.43±0.18 to 1.20±0.56 %ID/cc for [18F]FDG and 0.46±
0.23 to 1.30±0.62 %ID/cc for [18F]DPA-714 (pG0.0006 for
[18F]FDG and pG0.0058 for [18F]DPA-714, Fig. 4).
The objective of molecular in vivo imaging is to
visualize the process of interest, in our case inﬂammation
in an IBD model, but mainly to enable analysis and
quantiﬁcation of a dynamic process. In order to evaluate
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the potential of [18F]DPA-714 to achieve this goal, we
followed the inﬂammation over a period of 22 days in a
group of six animals. The ﬁrst images were acquired on
each rat 1 day before the instillation of the TNBS to
measure the basal value of [18F]DPA-714 uptake in the
middle of the colon for each rat. After induction, the
animals were imaged at different days (1, 2, 4, 8, 10,
and 22) as represented in Fig. 5. This ﬁgure indicates an
increase of [18F]DPA-714 uptake until day 8/10 after
which the mean signal decreased slowly to reach basal
value at 22 days post induction. A large standard
deviation was observed for the mean values at days 8,
10, and 22, illustrating the highly variable inter-individ-
ual evolution of the disease.
Fig. 1. H&E staining and immunohistochemical observations using TSPO antibody (NP155, red, DAPI in blue). In non-treated
rat: a H&E staining and d NP155; in rat receiving DSS in water during 7 days: b H&E staining and e NP155; and, in TNBS
instilled rats: c H&E staining and f NP155.
Fig. 2. Whole body PET images on control and DSS treated animals. [18F]FDG in a control and b treated animals; [18F]DPA-
714 in c control and d treated animals. Color scales are different ranging from 0 to 200 MBq/cc for [18F]FDG and to 500 MBq/cc
for [18F]DPA-714 images. Quantification of e [18F]FDG and f [18F]DPA-714 measured on PET images in area with highest uptake
within the colon on control and DSS treated rats.
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Discussion
IBD is a serious health issue, which appears to be increasing
throughout the Western world. It is a disease which does not
discriminate between ages, although it does tend to be
present in higher numbers among the weaker of society,
namely the young and aged groups. IBD, as a family of
diseases, including Crohn’s disease and UC, can in many
instances turn chronic, at which point there is no treatment
for the disease itself, only its symptoms. This in itself will
degrade the quality of life and result in additional medical
expenses, which could possibly be avoided by early
detection or improved diagnostics to evaluate the inﬂamma-
tory component of the disease. PET imaging, using an
appropriate radiotracer, offers this opportunity. It allows the
researcher/medical doctor to observe a difference at a
molecular level, which could aid in early diagnosis. This
diagnosis, however, is only as good as the tools that are
used. Thus far, the tools have not been focused on a speciﬁc
aspect of inﬂammation, but rather on a symptom of the
inﬂammation. Thus, they currently lack speciﬁc techniques
for imaging and detection of IBD. We are now capable of
producing improved tools and using them more effectively.
In this study, we investigated two IBD models reﬂecting
both local and diffuse inﬂammation of the digestive tract
using PET imaging. We demonstrate that with the use of an
adapted tracer [18F]DPA-714, we are able to detect,
visualize, and quantify a difference between the non-treated
animals and those that underwent the treatments in order to
induce IBD symptoms (as seen in Fig. 2 and 4).
The interest of this study was multifaceted. First, we
wanted to establish two different (reproducible) models of
inﬂammatory bowel disease, with different origins. Second,
Fig. 3. Gamma counting of the excised sections of intes-
tines revealed a difference of [18F]DPA-714 presence be-
tween the two groups. (*=p valueG0.0001) Results are
expressed in SUV.
Fig. 4. Whole body PET images on control and TNBS treated animals using [18F]FDG in a control and b treated animals;
[18F]DPA-714 in c control and d treated animals. Color scales are different ranging from 0 to 200 MBq/cc for [18F]FDG and to
500 MBq/cc for [18F]DPA-714 images. Quantification of e [18F]FDG and f [18F]DPA-714 measured on PET images in area with
highest uptake within the colon on control and TNBS treated rats. (*=pG0.0006 for [18F]FDG and pG0.0058 for [18F]DPA-714).
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we wanted to prove the relationship between tissular
expression of TSPO and the speciﬁc uptake of [18F]DPA-
714 obtained via molecular imaging. Third, to show that
imaging can provide a quantiﬁable difference between sick
and healthy subjects. Fourth and foremost, we wanted to
validate [18F]DPA-714 as a probe for peripheral inﬂamma-
tion, which has to date been used mainly for
neuroinﬂammation.
In addition to this list of objectives, we examined another
aspect of molecular imaging, speciﬁcally for PET, which
allows the user to follow the advancement and characterize
of a disease or any other molecular process of choice. This
approach was illustrated by the dynamic description of the
inﬂammatory status using [18F]DPA-714 in the TNBS model
(Fig. 5). Following the uptake of the radioligand in the
instillation area, we were able to demonstrate the ability to
detect varying levels of inﬂammation of the disease for each
individual animal.
Our ﬁrst objective had been to reproduce the models used
by the groups of Dr. Ostuni and Dr Seibel [11, 19]. This was
accomplished and used to detect inﬂammation in each
induced animal and subsequently veriﬁed with HE staining,
and also by labeling with Iba1 (macrophages) and NP-155
(TSPO 18kDa). In each case, we observed a marked
structural difference between the two groups as well as an
increase in signal on the treated animals from the markers.
The differences can be seen in images on Fig. 1d–f.
This invasive evaluation of inﬂammatory statue (using
biopsies) can certainly be characterized using PET as a
quantiﬁable imaging tool. Side effects of these intestinal
treatments (diarrhea and reduced gut motility) were found in
both DSS and TNBS models, respectively. These two
symptoms have a drastic impact on the size of the gut, the
ﬁrst one reducing the thickness making it difﬁcult to
visualize the intestine wall (often empty with a collapsed
lumen) and the second one with an increase of the diameter
due to the accumulation of feces. In the case of preclinical
imaging on small animals, the access to conventional CT
anatomical reference images is not possible due to the lack
of soft tissue contrast. The other limit in small animal
imaging is the spatial resolution of the PET camera in regard
to the thickness of the intestinal wall in rodents. This
resolution, coupled with the size of the structure impacts the
quantitative approach due to a high partial volume effect
artiﬁcially decreasing the uptake value observed in compar-
ison to the result expected in larger animal model or in
humans. To accurately compare data among different
animals, with different pathological models and different
tracers, we choose to deﬁne a small volume (5×3×2 voxels)
that we placed on the areas of highest uptake of each animal,
and then compared this volume between the groups.
Once we quantiﬁed the images, we found a difference
between the results of the two tracers on the same group.
The results on Figs. 2 and 5 revealed different levels of
signal when comparing the healthy groups to each other.
This means that the healthy group of the DSS [18F]FDG
animals yielded slightly different results than the same group
did with the [18F]DPA-714 radiotracer. This is understand-
able and explainable when looking at what each tracer is
actually targeting. [18F]FDG is a glucose analog which
indicates an increase of glucose consumption, which in itself
can be indicative of other on-going processes such as cancer,
cell regeneration, or muscle contraction as seen in peristalsis
[23, 24]. Fibroblasts also have an increase of glucose
consumption when they are exposed to inﬂammatory
mediators such as tumor necrosis factors (TNF) [25]. This
tracer has been described as a good marker of inﬂammatory
processes but it reﬂects global impact on different cell
populations and biological processes.
On the other hand, [18F]DPA-714 has not yet been shown
to be increased in different cell populations except in
immune white cells. This TSPO ligand has been presented
as a tracer with high afﬁnity and good speciﬁcity. Image
quantiﬁcation of [18F]DPA-714 uptake correlated with the
amount of TSPO, as published previously and provides
indirect information about white blood cell activation in the
tissue of interest [15, 26]. In the TNBS model, the uptake at
7 days of [18F]FDG and on day 8 of [18F]DPA-714 is higher
than in DSS model (Fig. 4). These differences illustrate a
higher level of local inﬂammation in this second model.
Another difﬁculty we faced in one of the preclinical
models was the localization of induced inﬂammation. Here,
in the second model, we had to choose a distance at which
the TNBS should be induced. We had to avoid the upper
digestive tract as this is the region in which the [18F]DPA-
714 is eliminated by, thus inhibiting us from distinguishing
the potential region of inﬂammation and the regular
elimination. Inducing the TNBS too close to the anus on
the other hand was also disadvantageous as the bladder is
located in the vicinity. This poses a problem as it is the renal
pathway by which [18F]FDG is eliminated, also obstructing
the image quantiﬁcation. Due to these constraints, we
decided to introduce the syringe at a depth of 4 cm from
the anus. In larger animals or human, these problems would
Fig. 5. Characterization of the TSPO expression over time in
a rat model of local inflammation within the colon (TNBS rat
model).
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not be signiﬁcant due to the fact that in human, [18F]DPA-
714 is also largely eliminated by the hepatic pathway but
with high gall bladder accumulation limiting the radioactiv-
ity signal in the intestine. In rats, the lack of gall bladder
prevents molecular imaging of the upper part of the intestine.
Beyond this, we used [18F]DPA-714 to determine the point
at which the level of TSPO was at its highest in the TNBS
model in order to characterize the dynamic inﬂammatory
processes in this model. This was done by acquiring images at
various time points post TNBS induction, illustrating the
possibility to repeat image acquisitions and the possibility to
follow the evolution of the disease in an individual patient.
While the data revealed the time point at which one can observe
the highest level of inﬂammation, one can also observe
heterogeneity, post peak, which revealed a large standard
deviation. The origin of the heterogeneity is most likely linked
to the disease severity. However, a direct correlation between
the uptake of [18F]DPA-714 and a clinical score of the disease
was not possible in this study due to the limited number of
animals used for the dynamic evaluation (n=6). This proof of
principle can of course be extrapolated to humans with a
protocol dedicated to the evaluation of therapeutic efﬁciency or
disease progression.
Conclusion
In this study, we report for the ﬁrst time, the ability to
distinguish a difference between IBD affected and
healthy animals using PET imaging and gamma counting
with the use of the TSPO radioligand [18F]DPA-714 in
two separate models. [18F]FDG also provided a positive
contrast in the intestine of sick animals. However, the
statistical signiﬁcance was less than that of the
[18F]DPA-714. Beyond this, we also demonstrated the
ability to follow a disease evolution over time with the
use of [18F]DPA-714. Studies such as these demonstrate
the potential applications of this TSPO ligand [18F]DPA-
714 which may improve the clinical diagnosis for
inﬂammatory bowel disease patients.
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